Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis
NCT06998628
Summary
Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints
Eligibility
Inclusion Criteria: * Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) \[9\] i.e., 28 joints disease activity score (DAS 28) \>2.6. * Patients receiving the conventional DMARDs. * Both sexes. * Age range between 18and 70 years old Exclusion Criteria: * Patients with retinal or cerebral hemorrhage. * Patients with renal and hepatic dysfunction. * Patients with hypersensitivity to study medications. * Pregnant and lactating females. * Patients receiving biological or synthetic DMARDs
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06998628